Sensei Biotherapeutics, Inc. (SNSE)
Largest Insider Buys in Sector
SNSE Stock Price History Chart
SNSE Stock Performance
About Sensei Biotherapeutics, Inc.
Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor …
Insider Activity of Sensei Biotherapeutics, Inc.
Over the last 12 months, insiders at Sensei Biotherapeutics, Inc. have bought $0 and sold $0 worth of Sensei Biotherapeutics, Inc. stock.
On average, over the past 5 years, insiders at Sensei Biotherapeutics, Inc. have bought $2.75M and sold $1.1M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 500 shares for transaction amount of $425 was made by Celebi John (President and CEO) on 2023‑09‑11.
List of Insider Buy and Sell Transactions, Sensei Biotherapeutics, Inc.
| 2023-09-11 | President and CEO | 500 0.002% | $0.85 | $425 | -6.91% | |||
| 2023-06-01 | Sale | 10 percent owner | 955,738 3.3509% | $1.58 | $1.51M | -40.07% | ||
| 2023-02-23 | 10 percent owner | 2,200 0.0071% | $1.61 | $3,539 | -36.42% | |||
| 2022-03-02 | 1,203 0.0037% | $3.20 | $3,850 | -49.40% | ||||
| 2022-03-02 | 10 percent owner | 1,203 0.0037% | $3.20 | $3,850 | -49.40% | |||
| 2022-03-01 | 2,458 0.0082% | $3.60 | $8,849 | -51.84% | ||||
| 2022-03-01 | 10 percent owner | 2,458 0.0082% | $3.60 | $8,849 | -51.84% | |||
| 2022-02-28 | 42 0.0001% | $3.60 | $151 | -52.91% | ||||
| 2022-02-28 | 10 percent owner | 42 0.0001% | $3.60 | $151 | -52.91% | |||
| 2022-02-25 | 2,500 0.0079% | $3.65 | $9,125 | -54.39% | ||||
| 2022-02-25 | 10 percent owner | 2,500 0.0079% | $3.65 | $9,125 | -54.39% | |||
| 2022-02-24 | 15,000 0.0483% | $3.63 | $54,450 | -53.26% | ||||
| 2022-02-24 | 10 percent owner | 15,000 0.0483% | $3.63 | $54,450 | -53.26% | |||
| 2022-02-23 | 2,500 0.0082% | $3.80 | $9,500 | -54.09% | ||||
| 2022-02-23 | 10 percent owner | 2,500 0.0082% | $3.80 | $9,500 | -54.09% | |||
| 2022-02-18 | 15,000 0.0473% | $3.97 | $59,550 | -56.93% | ||||
| 2022-02-18 | 10 percent owner | 15,000 0.0473% | $3.97 | $59,550 | -56.93% | |||
| 2022-02-17 | 4,949 0.0164% | $4.17 | $20,637 | -56.69% | ||||
| 2022-02-17 | 10 percent owner | 4,949 0.0164% | $4.17 | $20,637 | -56.69% | |||
| 2022-02-16 | 2,551 0.0083% | $4.25 | $10,842 | -57.85% |
Insider Historical Profitability
| Cambrian BioPharma Inc | 10 percent owner | 5231488 20.8% | $0.50 | 59 | 0 | <0.0001% |
| Peyer James | 5231488 20.8% | $0.50 | 59 | 0 | <0.0001% | |
| RICKS THOMAS G | director | 341769 1.3588% | $0.50 | 2 | 0 | <0.0001% |
| Celebi John | President and CEO | 111311 0.4426% | $0.50 | 1 | 0 | |
| Apeiron Investment Group Ltd. | 10 percent owner | 0 0% | $0.50 | 1 | 1 | <0.0001% |
Institutional Investor Ownership
| Newtyn Management | $976,741.00 | 3.71 | 930,230 | -40.83% | -$673,882.31 | 0.21 | |
| The Vanguard Group | $602,536.00 | 2.29 | 573,844 | +0.03% | +$202.65 | <0.0001 | |
| Renaissance Technologies | $222,000.00 | 0.84 | 211,000 | +47.03% | +$71,010.54 | <0.0001 | |
| Geode Capital Management | $143,165.00 | 0.54 | 136,318 | 0% | +$0 | <0.0001 | |
| Bridgeway Capital Management | $118,545.00 | 0.45 | 112,900 | 0% | +$0 | <0.01 |